Verition Fund Management LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,361 shares of the company’s stock, valued at approximately $649,000.
Several other hedge funds have also added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in Neurocrine Biosciences by 2.6% during the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after buying an additional 140,639 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Neurocrine Biosciences by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 181,751 shares of the company’s stock worth $11,135,000 after buying an additional 5,554 shares in the last quarter. Chicago Equity Partners LLC purchased a new stake in Neurocrine Biosciences during the fourth quarter worth $2,759,000. Moody Aldrich Partners LLC boosted its holdings in Neurocrine Biosciences by 13.2% during the third quarter. Moody Aldrich Partners LLC now owns 22,256 shares of the company’s stock worth $1,364,000 after buying an additional 2,591 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Neurocrine Biosciences during the third quarter worth $1,633,000.
Shares of NBIX stock opened at $84.89 on Wednesday. The company has a market cap of $7,599.86, a PE ratio of -51.76 and a beta of 0.31. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20. Neurocrine Biosciences, Inc. has a 12-month low of $39.21 and a 12-month high of $92.98.
In other news, insider Haig P. Bozigian sold 75,873 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $90.00, for a total value of $6,828,570.00. Following the completion of the sale, the insider now directly owns 18,041 shares in the company, valued at $1,623,690. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Darin Lippoldt sold 15,237 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. The disclosure for this sale can be found here. Insiders sold 399,589 shares of company stock valued at $32,443,795 over the last quarter. Company insiders own 4.80% of the company’s stock.
A number of analysts recently issued reports on NBIX shares. Needham & Company LLC increased their price target on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $95.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, January 15th. Deutsche Bank increased their price target on shares of Neurocrine Biosciences to $97.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. BidaskClub downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Jefferies Group increased their price target on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus target price of $95.23.
TRADEMARK VIOLATION NOTICE: “Verition Fund Management LLC Takes $649,000 Position in Neurocrine Biosciences, Inc. (NBIX)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2018/03/21/verition-fund-management-llc-takes-649000-position-in-neurocrine-biosciences-inc-nbix.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.